Intelligent Medicine Acquisition Corp. Class A Common Stock
IQMD
IQMD was delisted on the 26th of April, 2023.
20 hedge funds and large institutions have $71.9M invested in Intelligent Medicine Acquisition Corp. Class A Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
31.31% more ownership
Funds ownership: 0% → 31.31% (+31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
+$15.5M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$11.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.93M |
| 4 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$5.58M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$4.94M |
Top Sellers
IQMD Hedge Fund Activity: Q4 2021 in Review
20 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Intelligent Medicine Acquisition Corp. Class A Common Stock (IQMD) for Q4 2021, worth a combined $71.9M.
Buyers outnumbered sellers: 20 funds opened new IQMD positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Saba Capital Management, opening a new position worth an estimated $15.5M.
- 20 institutional investors held Intelligent Medicine Acquisition Corp. Class A Common Stock (IQMD) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $71.9M of Intelligent Medicine Acquisition Corp. Class A Common Stock stock for Q4 2021.
- 20 funds opened new Intelligent Medicine Acquisition Corp. Class A Common Stock positions in Q4 2021 and 0 closed out, a net change of +20 holders.
- The largest Intelligent Medicine Acquisition Corp. Class A Common Stock buyer in Q4 2021 was Saba Capital Management, an estimated $15.5M added.
Based on aggregated 13F filings for Q4 2021.